TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06723041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure Therapy
Description: Undergo true acupressure

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupressure Therapy - placebo
Description: Undergo sham acupressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure Therapy - self-administered
Description: Undergo self-administered acupressure

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupressure Therapy - self-administered
Description: Undergo self-administered acupressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive educational handouts

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Health Promotion and Education
Description: Receive educational handouts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06740851

Intervention type: PROCEDURE
Intervention: Touch® Trapeziometacarpal Joint Arthroplasty
Description: The intervention involves primary trapeziometacarpal joint (TMJ) arthroplasty using the Touch® prosthesis, a dual-mobility implant designed for the treatment of osteoarthritis in the thumb.
Study: NCT06744049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transfer Direct System (TDS)
Description: Class IIA medical device (according to rule 5 of Annex VIII of Regulation (EU) 2017/745 for medical devices). A semi-automated medical equipment designed to inject an embryo into the maternal uterine endometrium through the lumen of the female reproductive system.
Study: NCT06743503

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UB-VV400
Description: UB-VV400 is a third-generation, self-inactivating (SIN), replication-incompetent, lentiviral vector (LVV) investigational drug product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: In DF Stage 2, Rapamycin will be given in combination with UB-VV400. For subjects receiving rapamycin, rapamycin dosing will be once daily with a planned start date of Day 4 (approximately 72 hours after the administration of UB-VV400) and continuing for up to 60 days, as tolerated.
Study: NCT06745843

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: The patient information, informed consent form and questionnaire will collectively be distributed digitally or by mail to all patients.
Study: NCT06744790

Intervention type: DEVICE
Intervention: Linshom Continuous Predictive Respiratory Monitoring
Description: Observational study. Monitoring of Linshom, pulse oximetry and capnography data with comparison to current standard of care.
Study: NCT06743464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 MG
Description: Preoperative Rifaximin supplementation 550 mg twice daily from preoperatively 2 weeks to post op POD 1 to 7

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: SOC means Standard of care which means that the patient will revieve standard post op care followed at our insitute and other hospitals in India.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC
Description: SOC means Standard of care which means that the patient will revieve standard post op care followed at our insitute and other hospitals in India.
Study: NCT06743971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ocean sound concert
Description: intervention group listened to the ocean sound, the control group continued their daily care routines
Study: NCT06744829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon placement and inflation and removal of the Balloon
Description: STELLA Endogastric ballon will be inserted into the stomach and inflated with sterile saline solution and will remain in place for 6 months. After which the device will be removed
Study: NCT06743841

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Description: 60g of a nutritional supplement powder, divided into 2 daily intakes, one in the morning and one in the afternoon
Study: NCT05051059

Intervention type: OTHER
Group type: OTHER
Intervention: Functional outcome
Description: 3D-motion analysis and strength assessment
Study: NCT06743841

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control supplement
Description: 60g of a placebo supplement powder, divided into 2 daily intakes, one in the morning and one in the afternoon
Study: NCT06745869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercise training
Description: At the end of the training, participants will be asked to do an exercise session and this session will be observed. Training will continue until participants learn and apply the exercise correctly.~5-minute warm-up and cool-down periods will be applied at the beginning and end of each exercise session. Exercises will be done twice a day, morning and evening, for 8 weeks.~In order to follow the exercise, participants will be given diaphragmatic breathing exercise tracking cards with date and session information. In addition, participants will be followed up weekly on one of the rehearsal days to ensure their adaptation to the exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic breathing exercise training
Description: At the end of the training, participants will be asked to do an exercise session and this session will be observed. Training will continue until participants learn and apply the exercise correctly.~5-minute warm-up and cool-down periods will be applied at the beginning and end of each exercise session. Exercises will be done twice a day, morning and evening, for 8 weeks.~In order to follow the exercise, participants will be given diaphragmatic breathing exercise tracking cards with date and session information. In addition, participants will be followed up weekly on one of the rehearsal days to ensure their adaptation to the exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The intensity of the aerobic exercise program will be calculated for each participant using the Karvonen formula. Accordingly, each participant will be given a brisk walking program on a suitable surface, which will be created specifically for the individual to reach the target heart rate range within the scope of the aerobic exercise program; they will apply a 45-minute session, 3 days a week, for 8 weeks.
Study: NCT06743997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Drug (Eutropin Catridge, 48IU/Cartridge)
Description: Liqid somatropin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Drug (Eutropin Catridge, 48IU/Cartridge)
Description: Liqid somatropin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Drug (Eutropin, 4 IU/vial)
Description: Lyophilized somatropin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Drug (Eutropin, 4 IU/vial)
Description: Lyophilized somatropin
Study: NCT06744075

Intervention type: OTHER
Group type: OTHER
Intervention: Blood assessment
Description: ctDNA collection (venous blood draw) will occur at baseline, mid-treatment, and at the end of treatment
Study: NCT06745674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a mobile app-delivered Acceptance Commitment Therapy (ACT)
Description: The study utilized a specially tailored internet-based self-help ACT program for cancer patients. It consisted of an introductory module and six core intervention modules: (1) Refusing Avoidance; (2) Accepting Distress; (3) Living in the Present Moment; (4) Observing Yourself Psychologically; (5) Exploring Meaningful Values; and (6) Committing to Action. Each module, designed to take 30-60 minutes, was delivered over a two-week period.
Study: NCT06741930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: The Ketamine group received IV ketamine at a titrated dose of 0.5-1.0 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: The Midazolam group received IV midazolam at a titrated dose of 0.15-0.40 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The Propofol group received IV propofol at a titrated dose of 0.5-1.0 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.
Study: NCT06744998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch® (Baxter)
Description: HEMOPATCH® is an absorbable collagen pad intended for sealing and hemostasis
Study: NCT06745154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo nasal swab collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Undergo cognitive assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Given nicotine patches, gum, or lozenges

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive access to the Ohio Tobacco Quit Line

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Participate in counseling sessions
Study: NCT05051059

Intervention type: OTHER
Group type: OTHER
Intervention: Health related quality of life (HRQoL) assessment
Description: Quality of Life Questionnaire C-30 (QLQ-C30), Impact on Participation and Autonomy Questionnaire (IPAQ) and Musculoskeletal Tumor Society Score (MSTS)

Intervention type: OTHER
Group type: OTHER
Intervention: Health related quality of life (HRQoL) assessment
Description: Quality of Life Questionnaire C-30 (QLQ-C30), Impact on Participation and Autonomy Questionnaire (IPAQ) and Musculoskeletal Tumor Society Score (MSTS)
Study: NCT06546670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITU512
Description: ITU512 is an investigational, oral, low molecular weight (LMW) compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITU512
Description: ITU512 is an investigational, oral, low molecular weight (LMW) compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITU512
Description: ITU512 is an investigational, oral, low molecular weight (LMW) compound.
Study: NCT06125301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MS Sherpa
Description: MS sherpa® is a medical device, intended to support monitoring of persons with MS in order to give patients and their professional healthcare team(s) insight into the presence and progress of symptoms related to MS. MS sherpa® is a system consisting of a smartphone app for data collection and data presentation, a cloud service for data storage, analysis algorithms, and a clinician or research dashboard for user management and data visualization. The device measures the course of symptoms related to MS with respect to walking speed (average walking speed derived from the distance walked during a 2-minute walk), cognitive processing speed, number of correct answers on a smartphone variant of the symbol digit modalities test (SDMT) and patient reported outcomes, through predefined questionnaires regarding fatigue, amongst others. MS sherpa® measures changes in these parameters over time and shows these on an insights screen in the app and on the clinician dashboard.
Study: NCT05844319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tele-education
Description: The treatment of the patients will be carried out by tele-education method.
Study: NCT06546670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITU512
Description: ITU512 is an investigational, oral, low molecular weight (LMW) compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.
Study: NCT06073132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-203
Description: The investigational product is formulated as 1% topical ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-203
Description: The investigational product is formulated as 1% topical ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle-only control study medication is the same formulation as investigational product without active ingredient
Study: NCT05198583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Fit
Description: The intervention lasts a total of 8 weeks and is structured in 3 modules. The first module consists of a weekly strategy training in which problems resulting from executive dysfunction are addressed. Online games form the second module. These are games implemented online to promote EF through play. The third module is also based on games: The families receive several board games to play together at home. This third module is voluntary.
Study: NCT05841901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huang-long Zhi-xiao Granule
Description: The experimental group was given Huang-long Zhi-xiao Granule.1 dose per day, oral in 2 divided doses, 1 course every 4 weeks, for a total of 8 weeks of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huang-long Zhi-xiao Granule placebo
Description: The toncral group was given placebo Huang-long Zhi-xiao Granule.The course of treatment was the same as that of the experimental group.
Study: NCT05154825

Intervention type: OTHER
Intervention: Imaging-Observational
Description: Preoperative standing and supine, intraoperative pre- and post-correction, and postoperative standing imaging as well as imaging collected during follow-up exams for a year following surgery
Study: NCT05625503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: All patients routinely receive intra-arterial calcium channel blockers during transradial access for coronary angiography.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicardipine
Description: Calcium channel blocker
Study: NCT05882643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate to deep neuromuscular blockade
Description: * Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3 count, post-tetanic count \> 1)~* Rocuronium (intravenous, 1.0 mg/kg at induction period)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: shallow to minimal neuromuscular blockade
Description: * Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count \< 0.9)~* Rocuronium (intravenous, 0.3 mg/kg at induction period)
Study: NCT05298878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group: Virtual home-based rehabilitation plus usual outpatient care
Description: 14 supervised exercise virtual sessions with Kinesiologist and 10 independent exercise sessions. Each session lasts 40 minutes. The exercises consist of aerobic training; functional lower and upper body strengthening; balance; and flexibility exercises. During the first 10 minutes of the first session of each week, there is an educational session.~Week 1-2: three supervised virtual sessions Week 3-4: two supervised virtual sessions and one independent session. Week 5-8: one supervised virtual session and two independent sessions.
Study: NCT06207162

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task. There will also be a Resting state: Participants are not presented with any specific stimulus.
Study: NCT05438576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence enabled electrocardiogram (AI-ECG)
Description: An artificial intelligence algorithm which analyses ECG data and generates prediction probabilities for a diagnosis of cardiomyopathy.
Study: NCT05855993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve Glide Exercise with Ultra Sound
Description: A brief demonstration will be given to perform the nerve glides exercises to both group. The duration of exercise programmed is 15 minutes every 3 to 5 times per day for 4 weeks. Group A will perform exercise with ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Glide Exercise without Ultra Sound
Description: Group B will perform exercise for 10 minutes every 3 to 5 times per day without ultrasound.
Study: NCT06443593

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tablet VitaBliss vitamin B12 (2.2 mcg)
Description: Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tablet VitaBliss vitamin B12 (2.2 mcg) and Syrup Orofer (5 ml = 50 mg)
Description: Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral iron 25 mg from Emcure Pharmaceuticals Ltd. to be administered once daily for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tablet VitaBliss vitamin B12 (2.2 mcg) and Tablet Tayo (60000 IU)
Description: Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral vitamin D3 (60000 IU) from Eris Lifesciences Ltd to be administered once in 3 months for 24 weeks
Study: NCT06377592

Intervention type: OTHER
Intervention: Sample collection without intervention
Description: No Intervention
Study: NCT06020937

Intervention type: DIAGNOSTIC_TEST
Intervention: TDI
Description: Sniffin' Sticks Threshold and Identification Test

Intervention type: DIAGNOSTIC_TEST
Intervention: TDI
Description: Sniffin' Sticks Threshold and Identification Test

Intervention type: DIAGNOSTIC_TEST
Intervention: TDI
Description: Sniffin' Sticks Threshold and Identification Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Trigeminal Test
Description: Test the trigeminal smell answer by a device that releases air and a substance that stimulates the trigeminal response

Intervention type: DIAGNOSTIC_TEST
Intervention: Trigeminal Test
Description: Test the trigeminal smell answer by a device that releases air and a substance that stimulates the trigeminal response

Intervention type: DIAGNOSTIC_TEST
Intervention: Trigeminal Test
Description: Test the trigeminal smell answer by a device that releases air and a substance that stimulates the trigeminal response

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Evaluation by Montreal Cognitive Assessment
Description: Montreal Cognitive assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Evaluation by Montreal Cognitive Assessment
Description: Montreal Cognitive assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Anxiety and Depression questionnaire
Description: Specific test to evaluate patient's mood

Intervention type: DIAGNOSTIC_TEST
Intervention: Anxiety and Depression questionnaire
Description: Specific test to evaluate patient's mood

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Analogue Scale Ratings
Description: * Smell ability (How is your sense of smell right now? 0 cannot smell, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)~* Nasal breathing (How well can you breathe through your nose right now? 0 complete nasal obstruction, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Analogue Scale Ratings
Description: * Smell ability (How is your sense of smell right now? 0 cannot smell, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)~* Nasal breathing (How well can you breathe through your nose right now? 0 complete nasal obstruction, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Analogue Scale Ratings
Description: * Smell ability (How is your sense of smell right now? 0 cannot smell, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)~* Nasal breathing (How well can you breathe through your nose right now? 0 complete nasal obstruction, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)
Study: NCT05838235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity program
Description: The Adaptated Physical Activity program will consist of a Personalized Training Program
Study: NCT05921318

Intervention type: COMBINATION_PRODUCT
Intervention: Beijing protocol
Description: For patients \<55 years and HCT-CI≤ 3：Ara-C(4g/m2/day,-9 days),Bu(9.6mg/kg,-8 days to -6 days),Cy(1,800mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)~For patients ≥ 55 years or HCI-CI\>3：Ara-C(2g/m2/day,-10 days to -9 days),Bu(9.6mg/kg,-8 days to -6 days),Flu(30mg/m2/day,-6 days to -2 days),Cy(1,000mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days).
Study: NCT06020937

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of smell Questionnaire
Description: Patients will answer to a validated questionnaire
Study: NCT04741997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib Pill
Description: Encorafenib 450 mg will be administered orally once per day in continuous 28-day cycles
Study: NCT06020937

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of smell Questionnaire
Description: Patients will answer to a validated questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of smell Questionnaire
Description: Patients will answer to a validated questionnaire